Publications by authors named "Max Topp"

Claim this Profile
E
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.
Lukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, Markus Kreuz, Sofie-Katrin Kadel, Max S Topp

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3.
Tom van Meerten, Marie José Kersten, Gloria Iacoboni, Georg R Hess, Pim G N J Mutsaers, Max S Topp

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.
Maximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, Igor-Wolfgang Blau, Marie Harzer, Laura S Topp, Max S Topp

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma.
Jan H Frenking, Xiang Zhou, Kai Rejeski, Vivien Wagner, Patrick Costello, Max Topp

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.
Maximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, Igor-Wolfgang Blau, Marie Harzer, Laura S Topp, Max S Topp

Blood Cancer J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
Fabian Lang, Andreas Voss, Guido Kobbe, Christian Junghanss, Joachim Beck, Max Topp

Leuk Lymphoma· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Aaron C Logan, Max S Topp

Leukemia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
Max S Topp, Matthew Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes

Blood· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults.
Tobias Feuchtinger, Peter Bader, Marion Subklewe, Maike Breidenbach, Semjon Willier, Max Topp

Haematologica· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies.
Anna Fleischer, Sophia Kurth, Johannes Duell, Max Topp, Patrick-Pascal Strunz

J Immunother Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone Lymphoma.
Rudolf A Werner, Yingjun Zhi, Niklas Dreher, Samuel Samnick, Aleksander Kosmala, Max S Topp

Mol Imaging Biol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.
Jan H Frenking, Xiang Zhou, Vivien Wagner, Thomas Hielscher, Joseph Kauer, Max Topp

J Immunother Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Xiang Zhou, Vivien Wagner, Lukas Scheller, Emilia Stanojkovska, Christine Riedhammer, Max Topp

Br J Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
Thomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, Heiko Trautmann, Claus Meyer, Max S Topp

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden Moccia, Richard Greil, Max S Topp

Lancet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.
Tom van Meerten, John Kuruvilla, Kevin W Song, Catherine Thieblemont, Monique C Minnema, Max S Topp

Am J Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L Illert, Max S Topp

Nuklearmedizin· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Max S Topp

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [F]FDG.
Aleksander Kosmala, Johannes Duell, Simone Schneid, Sebastian E Serfling, Takahiro Higuchi, Max S Topp

Eur J Nucl Med Mol Imaging· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.
Johannes Duell, Alexander M Leipold, Silke Appenzeller, Viktoria Fuhr, Hilka Rauert-Wunderlich, Max S Topp

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Georg Kuhnert, Max S Topp

Leukemia· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
Johannes Duell, Andreas K Buck, Philipp E Hartrampf, Wiebke Schlötelburg, Simone Schneid, Max S Topp

J Nucl Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Sensitivity of Rapid Tests for SARS-CoV-2 Antigen.
Kerstin Knies, Isabell Wagenhäuser, Daniela Hofmann, Vera Rauschenberger, Michael Eisenmann, Max S Topp

Dtsch Arztebl Int· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.
Maria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, Malte von Bonin, Vladan Vucinic, Max S Topp

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Max S Topp

J Immunother Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis